Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company. Shareholders of Kimberly-Clark...
Kimberly-Clark CEO Mike Hsu told CNBC’s Jim Cramer that his company’s planned acquisition of Tylenol maker Kenvue will create value for shareholders, even as the pain...
Huggies, manufactured by Kimberly-Clark and Band-Aid, manufactured by Kenvue. Getty Images Kimberly-Clark announced Monday it’s struck an agreement to buy Kenvue in a deal valued at...
Trading information on Kenvue Inc., a consumer-health business spun off from Johnson & Johnson, is displayed on a screen during the company’s IPO at the New...
Kenvue’s interim CEO is defending Tylenol’s safety after President Donald J. Trump and Health Secretary Robert F. Kennedy Jr. linked the pain reliever to autism and...
